GeneDx Holdings Corp. (WGS) Stock Analysis

Q: What is the WGS stock price target?

Take-profit $118.42 (+87.6% upside). Target $118.42 (+87.6%), stop $58.72 (−7.5%), A.R:R 6.7:1.

Q: What are the risks of investing in WGS?

Earnings in 4 days (event risk); Negative momentum; Elevated risk factors; Momentum score 3.4/10 — below 4.5 minimum; Death cross — 50-day MA below 200-day MA.

Q: Is WGS overvalued or undervalued?

GeneDx Holdings Corp. trades at a P/E of N/A (forward 30.6). TrendMatrix value score: 7.5/10. Overall verdict: Hold.

Q: What do analysts say about WGS?

13 analysts cover WGS with a consensus score of 4.2/5. Average price target: $136.

Recovery setup

HoldVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-05-01

Healthcare · Diagnostics & Research

Earnings in 4 days (2026-05-04). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Hold if already holding. Not a fresh buy at $63.14, but acceptable to hold if already in. Reasons: Earnings in 4 days (event risk); Negative momentum.

$63.14+87.6% A.UpsideScore 6.0/10#1 of 25 Diagnostics & Research

Stop $58.72Target $118.42(analyst − 13%)A.R:R 6.7:1

Analyst target$136.11+115.6%9 analysts

$118.42our TP

$63.14price

$136.11mean

$177

Hold if already holding. Not a fresh buy at $63.14, but acceptable to hold if already in. Reasons: Earnings in 4 days (event risk); Negative momentum. Chart setup: Death cross but MACD improving, RSI 56. Mixed signals. Hold existing position. Score 6.0/10, moderate confidence.

Passes 4/8 gates (favorable risk/reward ratio, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 4d<=7d. Suitability: aggressive.

Thesis

Rewards

Strong earnings beat streak (4/4)

Attractive valuation

Strong growth profile

Risks

Earnings in 4 days (event risk)

Negative momentum

Elevated risk factors

Key Metrics

P/E (TTM)—

P/E (Fwd)30.6

Mkt Cap$1.8B

EV/EBITDA141.0

Profit Mgn-4.9%

ROE-7.6%

Rev Growth26.5%

Beta2.19

DividendNone

Rating analysts13

Quality Signals

Piotroski F8/9

Options Flow

P/C0.88neutral

IV121%elevated

Max Pain$84+33.0% vs spot

Concentration Risks(10-K Item 1A)

MEDIUMSupplierlimited number of suppliers
10-K Item 1A: 'We rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials'

Material Events(8-K, last 90d)

2026-03-02Item 1.01MEDIUM
GeneDx entered 00M Loan Agreement with Blackstone on Feb 27, 2026. Proceeds used to repay existing Perceptive credit agreement in full and for balance sheet optimization and general corporate purposes.
SEC filing →
2026-03-02Item 1.02MEDIUM
Existing Credit Agreement with Perceptive Credit Holdings IV, LP terminated and repaid in full on Feb 27, 2026 using proceeds from new Blackstone Loan Agreement.
SEC filing →
2026-03-02Item 2.03MEDIUM
Creation of 00M direct financial obligation via Blackstone term loan funded Feb 27, 2026. No reason cited beyond balance sheet optimization and general corporate purposes.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value7.515%1.13

Quality4.215%0.63

Growth9.115%1.36

Momentum3.410%0.34

Sentiment7.810%0.78

Insider Activity5.410%0.54

Peer Rank3.610%0.36

Technical Setup4.55%0.23

Risk Profile3.95%0.20

Catalyst7.55%0.38

Overall (Σ contributions)5.94

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume

0.3

Obv

1.0

Ma Position

1.0

Rsi

4.5

Macd

10.0

Volume distribution (falling OBV)Below 200-MA, MA slope -1.8%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

1.7

Value Rank

4.8

Growth Rank

8.0

GatesMomentum 3.4<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 4d<=7dINSIDER 0.24%=MODERATEA.R:R 6.7 ≥ 1.5No SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARRecoverySuitability: Aggressive

RSI

56 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $57.29Resistance $73.46

Price Targets

$59

$118

A.Upside+87.6%

A.R:R6.7:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeCautious

Risk Alerts

! Momentum score 3.4/10 — below 4.5 minimum

! Death cross — 50-day MA below 200-day MA

! EARNINGS_PROXIMITY:4d<=7d

Earnings

4/4 beats

Next Earnings2026-05-04 (4d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is WGS stock a buy right now?

Hold if already holding. Not a fresh buy at $63.14, but acceptable to hold if already in. Reasons: Earnings in 4 days (event risk); Negative momentum. Chart setup: Death cross but MACD improving, RSI 56. Mixed signals. Hold existing position. Target $118.42 (+87.6%), stop $58.72 (−7.5%), A.R:R 6.7:1. Score 6.0/10, moderate confidence.

What is the WGS stock price target?

Take-profit target: $118.42 (+87.6% upside). Target $118.42 (+87.6%), stop $58.72 (−7.5%), A.R:R 6.7:1. Stop-loss: $58.72.

What are the risks of investing in WGS?

Earnings in 4 days (event risk); Negative momentum; Elevated risk factors.

Is WGS overvalued or undervalued?

GeneDx Holdings Corp. trades at a P/E of N/A (forward 30.6). TrendMatrix value score: 7.5/10. Verdict: Hold.

What do analysts say about WGS?

13 analysts cover WGS with a consensus score of 4.2/5. Average price target: $136.

What does GeneDx Holdings Corp. do?GeneDx is a genomics diagnostics company specializing in exome and genome sequencing for rare and pediatric genetic...

GeneDx is a genomics diagnostics company specializing in exome and genome sequencing for rare and pediatric genetic diseases, performing all sequencing at its Gaithersburg, Maryland facility. Revenue comes from third-party payor reimbursement for diagnostic tests including ExomeDx and GenomeDx. The company holds GeneDx Infinity, one of the largest rare disease genomic datasets, supporting clinical testing and biopharma partnerships.